'iPS cells' ranks 21st in popular themes, regains spotlight with world's first clinical use of myocardial sheet

★ Popular Themes ? Top 10

1. Housing-related

2. Semiconductors

3. Regional banks

4. Autonomous vehicles

5. Physical AI

6. TOPIX Core 30

7. Banks

8. Artificial intelligence

9. Data centers

10. Cybersecurity

"iPS cells" ranked 21st in the "Popular Theme Ranking" compiled by Minkabu and Kabutan.

iPS cells are "pluripotent cells" capable of differentiating into virtually any cell in the body, and have attracted significant attention as a cutting-edge biotechnology underpinning next-generation medicine. Professor Shinya Yamanaka of Kyoto University was awarded the Nobel Prize in Physiology or Medicine in 2012. Among the government's 17 strategic fields, "drug discovery and advanced medicine" is included, and the application of iPS cells in the medical field is once again drawing renewed focus.

In particular, after the close of trading on the 29th, Cuorips Inc. <4894>, a regenerative medicine venture originating from Osaka University, announced that the first transplant surgery following insurance coverage listing of its myocardial sheet (regenerative medicine product) "Re-Heart" was successfully completed without incident. This marks the first time in the world that an iPS-derived product has been used to treat a patient in a clinical setting.

Among iPS cell-related developments, attention is also being paid to the rollout of "Amsheply," a Parkinson's disease treatment developed by Sumitomo Pharma Co., Ltd. <4506>, which received conditional manufacturing and marketing approval from the Ministry of Health, Labour and Welfare in March of this year alongside "Re-Heart." In addition, the movements of CellSeed Inc. <7776>, ReproCELL Incorporated <4978>, Heartseed Inc. <219A>, HEALIOS K.K. <4593>, and K Pharma, Inc. <4896> are drawing interest.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.